BRPI0707666A2 - compostos e composiÇÕes como inibidores de proteÍna cinase - Google Patents

compostos e composiÇÕes como inibidores de proteÍna cinase Download PDF

Info

Publication number
BRPI0707666A2
BRPI0707666A2 BRPI0707666-5A BRPI0707666A BRPI0707666A2 BR PI0707666 A2 BRPI0707666 A2 BR PI0707666A2 BR PI0707666 A BRPI0707666 A BR PI0707666A BR PI0707666 A2 BRPI0707666 A2 BR PI0707666A2
Authority
BR
Brazil
Prior art keywords
methyl
pyrimidin
ylamino
phenyl
trifluoromethyl
Prior art date
Application number
BRPI0707666-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Qiang Ding
Pingda Ren
Qiong Zhang
Xia Wang
Taebo Sim
Pamela A Albaugh
Nathanael S Gray
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of BRPI0707666A2 publication Critical patent/BRPI0707666A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0707666-5A 2006-02-06 2007-02-06 compostos e composiÇÕes como inibidores de proteÍna cinase BRPI0707666A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77104506P 2006-02-06 2006-02-06
US60/771,045 2006-02-06
PCT/US2007/003319 WO2007092531A2 (en) 2006-02-06 2007-02-06 Compounds and compositions as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0707666A2 true BRPI0707666A2 (pt) 2011-05-10

Family

ID=38255301

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0707666-5A BRPI0707666A2 (pt) 2006-02-06 2007-02-06 compostos e composiÇÕes como inibidores de proteÍna cinase

Country Status (10)

Country Link
US (1) US20090069327A1 (enExample)
EP (1) EP1981870A2 (enExample)
JP (1) JP2009525978A (enExample)
KR (1) KR20080092412A (enExample)
CN (1) CN101421262A (enExample)
AU (1) AU2007212345A1 (enExample)
BR (1) BRPI0707666A2 (enExample)
CA (1) CA2637225A1 (enExample)
RU (1) RU2008135690A (enExample)
WO (1) WO2007092531A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200811134A (en) 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
PL2300013T5 (pl) 2008-05-21 2025-04-28 Takeda Pharmaceutical Company Limited Pochodne fosforu jako inhibitor kinazy
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
CA2729012A1 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
US9044466B2 (en) * 2010-08-07 2015-06-02 The Research Foundation For The State University Of New York Oral compositions comprising a zinc compound and an anti-microbial agent
AU2011337461B2 (en) 2010-12-02 2015-04-02 Bisichem Co., Ltd. Novel purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against Raf kinase, containing same as active ingredient
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
SG10201604682VA (en) 2011-06-10 2016-07-28 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
US9061028B2 (en) 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Egfr発動性がんの細胞増殖阻害用化合物
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CA3015417A1 (en) 2016-03-01 2017-09-08 Propellon Therapeutics Inc. Inhibitors of wdr5 protein-protein binding
DK3423451T3 (da) 2016-03-01 2022-11-28 Propellon Therapeutics Inc Inhibitorer af wdr5-protein-proteinbinding
CN109952303B (zh) * 2016-10-14 2022-10-21 林伯士拉克许米公司 Tyk2抑制剂及其用途
CN113164478B (zh) * 2018-09-13 2024-10-11 南加州大学 新型fgfr抑制剂及其用途
CN113795256B (zh) * 2019-02-14 2024-05-03 布里奇恩生物科学公司 治疗癌症的fgfr抑制剂
JP7588224B2 (ja) 2020-10-05 2024-11-21 エンライブン インコーポレイテッド Bcr-ablチロシンキナーゼの阻害のための5-及び6-アザインドール化合物
TW202304889A (zh) * 2021-04-03 2023-02-01 大陸商海南耀臻生物醫藥科技有限公司 作為fgfr抑制劑的雜環化合物及其應用
WO2024159094A1 (en) * 2023-01-27 2024-08-02 Enliven Inc. Pyrimidinyl (hetero)aromatic aminopyridine compounds for inhibition of raf kinases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189729B2 (en) * 2003-09-30 2007-03-13 Irm Llc Methods and compositions as protein kinase inhibitors
US7880000B2 (en) * 2004-05-07 2011-02-01 Amgen Inc. Protein kinase modulators and method of use

Also Published As

Publication number Publication date
EP1981870A2 (en) 2008-10-22
RU2008135690A (ru) 2010-03-20
WO2007092531A3 (en) 2007-10-18
KR20080092412A (ko) 2008-10-15
CA2637225A1 (en) 2007-08-16
WO2007092531A2 (en) 2007-08-16
AU2007212345A1 (en) 2007-08-16
US20090069327A1 (en) 2009-03-12
JP2009525978A (ja) 2009-07-16
CN101421262A (zh) 2009-04-29

Similar Documents

Publication Publication Date Title
BRPI0707666A2 (pt) compostos e composiÇÕes como inibidores de proteÍna cinase
AU2007317349B2 (en) Compounds and compositions as protein kinase inhibitors
AU2008247442B2 (en) Compounds and compositions as c-kit and PDGFR kinase inhibitors
AU2007305016B2 (en) Compounds and compositions as protein kinase inhibitors
US7868018B2 (en) Compounds and compositions as protein kinase inhibitors
US8268850B2 (en) Pyrimidine derivatives and compositions as C-kit and PDGFR kinase inhibitors
US20090181991A1 (en) Compounds and compositions as protein kinase inhibitors
EP1940844B1 (en) Compounds and compositions as protein kinase inhibitors
BRPI0614578A2 (pt) composto, composição farmacêutica como inibidores de proteìna cinases, bem como seu método e uso
US20100184791A1 (en) Compounds and compositions as c-kit and pdgfr kinase inhibitors
MX2007016066A (es) Derivados de bencimidazol sustituidos por pirimidina como inhibidores de cinasa de proteina.
MX2008009925A (en) Compounds and compositions as protein kinase inhibitors

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A E 5A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.